One Drug Just Wiped Out 44% of Natco Pharma's Revenue. Here's a Concept Worth Knowing.

reported Q1 FY27 revenue of ₹735.2 crore, down 44.7% year-on-year. Net profit fell 57% to ₹206.5 crore. The cause: weak sales of lenalidomide, its generic cancer drug, previously a major international revenue driver. The segment breakdown tells the real story. Domestic formulations actually grew, from ₹107 crore to ₹136.4 crore. API business grew too. The entire collapse came from international formulations, which fell from ₹1,120.9 crore to ₹477.1 crore, over 55% down in that segment alone. This is revenue concentration risk. Generic drug makers often get a temporary exclusivity window to sell a drug before competitors enter and pricing collapses. During that window, revenue can be extraordinary. Once it ends, sales can fall off a cliff almost overnight, which is what appears to have happened here. The lesson generalizes well. Any company where a large share of revenue depends on one product or one temporary advantage carries this same risk, even if the rest of the business is healthy. Natco's domestic and API segments both grew, proof the company isn't broken, but concentration in one drug made the headline look far worse than the underlying business. The takeaway. When one product drives an outsized share of revenue, that strength eventually becomes a vulnerability. Worth checking concentration before assuming a strong quarter repeats.